ArticleRevista de neurologia2025
[Landau-Kleffner Syndrome and Continuous Spike-and-Wave During Sleep Syndrome: Comparison of Clinical, Neurophysiological, and Neuropsychological Characteristics].
Article in Revista de neurologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLandau-Kleffner Syndrome (LKS) is a subtype of epileptic encephalopathy with spike-wave activation during sleep (EESWAS), characterized by acquired aphasia associated with the emergence of epileptiform abnormalities. PATIENTS AND
methodsA cross-sectional descriptive study was conducted in a tertiary hospital, involving one group of children with LKS and another with EESWAS. The aim was to compare the clinical, neurophysiological, and neuropsychological aspects of both groups.
resultsSeven patients with LKS and seven patients with EE-SWAS were analyzed; the samples were homogeneous in terms of sex, etiology, and type of electroencephalographic pattern. The mean ages of onset were 3.6 years in the LKS group, debuting with language and behavioral regression in 100% (five patients with expressive language impairment only), and 4 years in the EE-SWAS group, debuting with epilepsy in 100%, followed by behavioral regression. In 57% of the LKS group, evolving epilepsy was observed with predominantly posterior epileptic abnormalities during wakefulness. The mean duration of continuous spike-and-wave activity during sleep (SWAS) was longer in the LKS group (3.7 vs 1.8 years). Corticosteroids was the most effective treatment, with 86% of patients in both groups showing improvement. On a neuropsychological level, cognitive impairment was observed in 71% of the LKS group versus 43% in the EE-SWAS group; attention difficulties were present in all EE-SWAS patients and 85% of LKS patients.
conclusionsEE-SWAS is characterized by cognitive-behavioral regression, with corticosteroids being the treatment of choice. LKS is a subtype of epilepsy within this group, with distinct features such as initial language impairment, posterior electroencephalogram (EEG) activity, and a longer duration of SWAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.